FDA Approval of Orphan Drug Indications for Pediatric Patients, 2011-2023

被引：0
|
作者：
Kakkilaya, Apoorva [1 ]
Shahzad, Mahnum [2 ]
Bourgeois, Florence T. [3 ,4 ,5 ]
机构：
[1] Univ Texas Med Branch, John Sealy Sch Med, Galveston, TX USA
[2] Harvard Med Sch, Dept Populat Med, Harvard Pilgrim Hlth Care Inst, Boston, MA USA
[3] Harvard Med Sch, Harvard MIT Ctr Regulatory Sci, Boston, MA USA
[4] Harvard Med Sch, Dept Pediat, Boston, MA USA
[5] Boston Childrens Hosp, Computat Hlth Informat Program, Pediat Therapeut & Regulatory Sci Initiat, Boston, MA USA
来源：
JAMA PEDIATRICS | 2025年 / 179卷 / 02期
关键词：
D O I：
10.1001/jamapediatrics.2024.5280
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
引用
收藏
页码：203 / 205
页数：3
相关论文
共 46 条
  • [21] FDA Approval of Cardiac Valve Devices Implanted in a National Cohort of Pediatric Patients, 2016-2022
    Wunnava, Susmitha
    Miller, Timothy A.
    Nathan, Meena
    Bourgeois, Florence T.
    JAMA PEDIATRICS, 2025,
  • [22] Children get their due - A study of pediatric epilepsy patients before drug approval
    Shields, W. Donald
    NEUROLOGY, 2008, 70 (21) : 1946 - 1947
  • [23] Response to FDA draft guidance on pediatric IBD drug approval trials: A consensus statement from the IBD Porto Group
    Turner, Dan
    Russell, Richard K.
    Wine, Eytan
    de Carpi, Javier Martin
    de Ridder, Lissy
    Shouval, Dror
    Dias, Jorge Amil
    Assa, Amit
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2025, 80 (01): : 238 - 241
  • [24] An Illustrative Example from the PaVe-GT Program for Navigating FDA Orphan Drug and Rare Pediatric Disease Designation Applications
    Lomash, Richa Madan
    Shchelochkov, Oleg
    Chandler, Randy J.
    Toney, London
    Portero, Deanna
    Venditti, Charles P.
    Pariser, Anne
    Ottinger, Elizabeth
    MOLECULAR THERAPY, 2023, 31 (04) : 776 - 777
  • [25] Pharmacogenomic Information in FDA-Approved Drug Labels: Application to Pediatric Patients
    Green, D. J.
    Mummaneni, P.
    Kim, I. W.
    Oh, J. M.
    Pacanowski, M.
    Burckart, G. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 (06) : 622 - 632
  • [26] The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians
    Subbiah, V.
    Solit, D. B.
    Chan, T. A.
    Kurzrock, R.
    ANNALS OF ONCOLOGY, 2020, 31 (09) : 1115 - 1118
  • [27] Analysis of Mortality and Life Expectancy Determinants Among 5,791 Deceased Pneumoconiosis Patients - Jiangsu Province, China, 2011-2023
    Zhu, Hangju
    Zhou, Lang
    Zhou, Jinyi
    Han, Lei
    Wu, Ming
    CHINA CDC WEEKLY, 2024, 6 (52): : 1417 - 1424
  • [28] Quantification of US Food and Drug Administration Premarket Approval Statements for High-Risk Medical Devices With Pediatric Age Indications
    Lee, Samuel J.
    Cho, Lauren
    Klang, Eyal
    Wall, James
    Rensi, Stefano
    Glicksberg, Benjamin S.
    JAMA NETWORK OPEN, 2021, 4 (06) : E2112562
  • [29] Performance status restrictions in clinical trials leading to US food and drug administration (FDA) drug approval: A cross-sectional study of a decade (2014-2023)
    Iannantuono, G. M.
    Filetti, M.
    Giudice, E.
    Sganga, S.
    Chandran, E. B. A.
    Xue, E.
    Lombardi, P.
    Rosenfeld, R.
    Rapisarda, E.
    Ferri, L.
    De Rubeis, G.
    Lorusso, D.
    Floudas, C.
    Gulley, J. L.
    Apolo, A. B.
    Lee, J-M.
    Karzai, F.
    Altamura, V.
    Scambia, G.
    Daniele, G.
    ANNALS OF ONCOLOGY, 2024, 35 : S956 - S957
  • [30] FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphoma
    Merino, Margret
    Kasamon, Yvette
    Li, Hongshan
    Ma, Lian
    Leong, Ruby
    Zhou, Jiaxi
    Reaman, Gregory
    Chambers, Wiley
    Richardson, Nicholas
    Theoret, Marc
    Pazdur, Richard
    Gormley, Nicole
    PEDIATRIC BLOOD & CANCER, 2022, 69 (08)
12345